LivaNova to Acquire ImThera Medical, Inc.
LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has entered into an agreement to acquire the remaining outstanding interests in ImThera Medical, Inc. (“ImThera”). Headquartered in San Diego, Calif., ImThera is a privately held company focused on neurostimulation for the treatment of obstructive sleep apnea (“OSA”). ImThera manufactures an implantable device that stimulates multiple tongue muscles via the hypoglossal nerve, which opens the airway while a patient is sleeping.
“The ImThera device is highly aligned with our existing Neuromodulation business, and we are extremely excited about the opportunity to optimize the technology and fold it into our universal platform. In the near term, we will focus on expanding ImThera’s current commercial presence in the European market, while advancing enrollment in a U.S. Food and Drug Administration (FDA) pivotal trial,” said Damien McDonald, LivaNova’s Chief Executive Officer. “The OSA market is large and growing, with many unmet needs. With our strong commercial capabilities and robust manufacturing, we look forward to bringing this innovative technology to the large patient population that has been unsuccessful with other treatments, allowing them to improve their quality of life.”
Patients with OSA can experience impaired daytime functionality, along with severe comorbidities such as heart failure and stroke. ImThera’s implantable device received CE Mark in 2012 and is indicated for patients with moderate to severe OSA who are unable or unwilling to use continuous positive airway pressure (“CPAP”) therapy. For these patients, the device is designed to reduce or eliminate sleep apnea, as demonstrated through clinical studies and its initial commercial use in Europe. Enrollment in a pivotal study is currently under way with the FDA to obtain premarket approval for the OSA implant.
“Adding ImThera and its obstructive sleep apnea device to our portfolio will strengthen our position as a leader in the field of neuromodulation,” said Jason Richey, LivaNova's President of North America and General Manager of the Neuromodulation business.
LivaNova has been an investor in ImThera since 2011 and has agreed to pay up to approximately $225 million to acquire the remaining outstanding interests of ImThera. Up-front costs are approximately $78 million with the balance paid on a schedule driven by regulatory and sales milestones. The deal is projected to be near-term accretive and is expected to close in early 2018 (subject to approvals and other customary closing conditions).
“ImThera Medical shares LivaNova’s mission to help patients live longer, better lives. We are proud of the accomplishments we have made in developing an effective CPAP alternative for individuals suffering from OSA. This acquisition will benefit healthcare providers, shareholders and most of all, the patients who are at the heart of everything we do,” said Marcelo Lima, ImThera’s Founder, President and Chief Executive Officer. “This is the culmination of several years of hard work by our team of dedicated professionals. We welcome the opportunity to become part of the LivaNova family and look forward to the continued evolution of our product.”
About ImThera Medical, Inc.
ImThera Medical is a global leader in neurostimulation for the treatment of obstructive sleep apnea. Headquartered in San Diego, ImThera was founded to improve the lives of patients suffering from the debilitating effects of OSA. ImThera’s sleep therapy product is comprised of an implanted small generator and multi-channel electrode lead, along with an external handheld remote control that can start, stop or pause therapy. ImThera collaborates with the world’s top scientists and medical experts in sleep medicine, and its product is commercially available in several countries outside the United States.
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe the Company’s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this press release are based on information presently available to LivaNova and assumptions that the Company believes to be reasonable, but are inherently uncertain. As a result, the Company’s actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company’s control. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning closing of the proposed acquisition of ImThera, entry into the OSA space, developing the ImThera device as an important growth platform, investing in the clinical studies, regulatory approvals, product enhancements and other steps needed to launch this device commercially in new markets, developing ImThera as a positive addition to the Company’s neuromodulation portfolio, offering patients the most advanced OSA therapy, offering a significant new therapy to patients with OSA, adding clinical study sites for ImThera’s implantable device, bringing a superior technology to market and anticipating that this transaction will meet all LivaNova long-term financial metrics and internal standards. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-4 and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova. LivaNova does not give any assurance (1) that LivaNova will achieve its expectations, or (2) concerning any result or the timing thereof.
All information in this press release is as of the date of its release. The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this press release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this press release.
For more information, please visit www.livanova.com .
LivaNova PLC Investor Relations and Media
Karen King, +1 (281) 228-7262
Vice President, Investor Relations & Corporate Communications
Deanna Wilke, +1 (281) 727-2764
Corporate External Communications Manager
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
2018 UL International Crown to Be Staged in Incheon October 4-725.9.2018 13:00 | Tiedote
2018 UL International Crown will be held October 4-7 at Jack Nicklaus Golf Club Korea in Songdo, Incheon Metropolitan City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005024/en/ 2018 UL International Crown will be held October 4-7 at Jack Nicklaus Golf Club Korea in Songdo, Incheon Metropolitan City. Incheon Metropolitan City is not sparing any effort to support the event as an Ambassador Partner. The most high-profile biennial golf tournament on the LPGA Tour, the third UL International Crown to take place with the second held in Chicago in 2016. 32 players from the eight countries will compete in the four-day match-play event for the “Crown.” (Graphic: Business Wire) The most high-profile biennial golf tournament on the LPGA Tour, a first-of-its-kind team match-play competition featuring the best women golfers from the top eight countries around the world, is being played outside the United States for the first t
Abu Dhabi's Fund Agreed Friendly TOB with MINDOL25.9.2018 12:59 | Tiedote
Abu Dhabi Dubai STOB Series 22 Investment Limited Partnership (”AbuDhabi22”as follows) and MINDOL HOLDINGS LIMITED (”MINDOL” as follows) which is listed on the Coinsuper Exchange in Hong Kong (https://www.coinsuper.com) agreed AbuDhabi22 to get 33% of crypto currency MINDOL (MIN)(http://mindol.net) that MINDOL issued by TOB. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005523/en/ The world audition of the Hollywood movie "TO DO & DIE" planned to be released worldwide in 2020! (Graphic: Business Wire) Strengthen strategic partnership with MINDOL by implementing TOB. Both of companies chose TOB as strategic approach to make a purchase at a stable price because acquisition price that AbuDhabi22 planned would be expected to significantly exceed with purchases via regular exchanges. TOB STAGE 1 has already finished and now TOB is being implemented at the purchase price of TOB STAGE 2. As a management vision for 2019, MIND
Brentwood Borough Council Stays Ahead of the Game with UniPrint/Azure Cloud Print Solution25.9.2018 12:18 | Tiedote
UniPrint.net announced today their successful secure cloud print deployment with Brentwood Borough Council in Essex, UK. In 2016, the Council released a report entitled “Vision for Brentwood, 2016-2019”. In it, they outlined their goals to better the lives of their constituents, and those goals included reducing costs and streamlining services. After examining their existing infrastructure, they made the decision to become the 1st UK council to move 100% of its systems and infrastructure to the cloud. “We wanted to create a very easy delivery of people’s desktops no matter where they were, whether it was a coffee shop, their home, or one of our sites,” said Tim Huggins, ICT Manager at Brentwood Borough Council. This presented a multitude of challenges, but one of the biggest was printing. “We approached our common provider,” said Huggins. “But it became quite evident very quickly that they had no solution, and we were way ahead of the game with our concepts and what we were trying to d
GSMA Reveals First Details for MWC19 Barcelona25.9.2018 10:00 | Tiedote
The GSMA today announced the first details of MWC19 Barcelona (formerly Mobile World Congress), including keynote speakers, prominent participating companies, programmes and events. MWC19 Barcelona will take place 25-28 February 2019, with events being staged at Fira Gran Via, Fira Montjuïc and La Farga L’Hospitalet. The GSMA expects that more than 107,000 professionals from over 200 countries and territories, representing a wide range of industry sectors, will attend MWC19 Barcelona. Under the event theme of “Intelligent Connectivity”, MWC19 Barcelona will highlight the intersection of “hyper-connectivity”, enabled by 5G and the Internet of Things (IoT), and “intelligence”, delivered by artificial intelligence (AI) and big data. In addition to the core elements of intelligent connectivity, MWC19 will explore the key topics of Content, Digital Trust, Digital Wellness and The Future. “Underpinned by 5G and AI, intelligent connectivity is a major technological force that will shape how t
AMRA Appoints Eric Converse as CEO25.9.2018 10:00 | Tiedote
AMRA Medical (“AMRA”), the international leader in body composition analysis, announced today that Eric Converse has been appointed as its new Chief Executive Officer (CEO). Starting on the 1st of October, Converse will assume the executive leadership from Tommy Johansson, who has been with AMRA since its establishment and will continue as an owner of the company. Tommy Johansson commented, “After guiding AMRA to become the dynamic, international digital health company it is today, I have concluded that it is time for me to slow down. Eric’s expertise across our main markets in both Europe and the US will prove invaluable in the years ahead. Eric is an experienced and daring leader with a reputation for nurturing talented teams to their full potential, and I am very enthusiastic to hand over the leadership of AMRA to him. I would like to take the opportunity to thank my colleagues, our collaborators, and our partners for seven fantastic years.” Before joining AMRA, Converse spent three
WIPO and IFPMA Launch New Online Patent-Search Resource to Help Health Agencies Procure Medicines25.9.2018 10:00 | Tiedote
WIPO and the research-based pharmaceutical industry today launched a new online tool designed to help procurement agencies better understand the global patent status of medicines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005088/en/ The Patent Information Initiative for Medicines (Pat-INFORMED) is a unique resource where patent holders provide information about patents covering approved medicines through a free, open access database. This new public database became operational today, along with a platform where procurement agencies can make direct enquiries to companies. Pat-INFORMED is a partnership between WIPO and the International Federation of Pharmaceutical Manufacturers and Associations, IFPMA, the global trade association representing the research-based pharmaceutical industry. Pat-INFORMED originated in the industry’s efforts to add clarity to patent information about medicines. WIPO’s globally recognized
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme